Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ729MR)

This product GTTS-WQ729MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ729MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3377MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ2856MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ5676MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ162MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ4805MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ2785MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ216MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ15262MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW